Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials

被引：0
|
作者：
Siegel, D. S. [1 ]
Martin, T. [2 ]
Nooka, A. [3 ]
Harvey, R. D. [3 ]
Vij, R. [4 ]
Niesvizky, R. [5 ]
Badros, A. Z. [6 ]
Jagannath, S. [7 ]
McCulloch, L. [8 ]
Rajangam, K. [8 ]
Lonial, S. [3 ]
机构：
[1] John Theurer Canc Ctr, Hackensack, NJ USA
[2] UCSF, San Francisco, CA USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[7] Mt Sinai Med Ctr, New York, NY 10029 USA
[8] Onyx Pharmaceut Inc, San Francisco, CA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
42
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [11] An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    Prince, H. Miles
    Schenkel, Brad
    Mileshkin, Linda
    [J]. LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 46 - 55
  • [12] Incidence and Management of Renal Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Shah, Jatin J.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 19 - 23
  • [13] Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
    Siegel, David S.
    Martin, Thomas
    Wang, Michael
    Vij, Ravi
    Jakubowiak, Andrzej J.
    Lonial, Sagar
    Trudel, Suzanne
    Kukreti, Vishal
    Bahlis, Nizar
    Alsina, Melissa
    Chanan-Khan, Asher
    Buadi, Francis
    Reu, Frederic J.
    Somlo, George
    Zonder, Jeffrey
    Song, Kevin
    Stewart, A. Keith
    Stadtmauer, Edward
    Kunkel, Lori
    Wear, Sandra
    Wong, Alvin F.
    Orlowski, Robert Z.
    Jagannath, Sundar
    [J]. BLOOD, 2012, 120 (14) : 2817 - 2825
  • [14] Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
    Chari, Ajai
    Stewart, A. Keith
    Russell, Stuart D.
    Moreau, Philippe
    Herrmann, Joerg
    Banchs, Jose
    Hajek, Roman
    Groarke, John
    Lyon, Alexander R.
    Batty, George N.
    Ro, Sunhee
    Huang, Mei
    Iskander, Karim S.
    Lenihan, Daniel
    [J]. BLOOD ADVANCES, 2018, 2 (13) : 1633 - 1644
  • [15] A phase ll study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma
    Siegel, D.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A.
    Lonial, S.
    Trudel, S.
    Kukreti, V
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F.
    Somlo, G.
    Zonder, J.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B.
    Rajangam, K.
    Orlowski, R.
    Jagannath, S.
    [J]. ONKOLOGIE, 2013, 36 : 38 - 39
  • [16] Overview and Management of Cardiac and Pulmonary Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Wang, Michael
    Cheng, Jie
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 24 - 30
  • [17] Single-agent Aredia for relapsed/refractory multiple myeloma.
    Berenson, JR
    Webb, IJ
    Anderson, K
    Schlossman, R
    Vescio, R
    Doss, D
    Goon, B
    Swift, R
    VonTeichert, J
    Kowalski, M
    Seaman, J
    [J]. BLOOD, 1999, 94 (10) : 307B - 307B
  • [18] Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials
    Zou, Yandun
    Ma, Xiaoyan
    Yu, Haiying
    Hu, Chunling
    Fan, Limei
    Ran, Xuehong
    [J]. ONCOTARGET, 2017, 8 (24) : 39805 - 39817
  • [19] A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Kunkel, L.
    Wear, S. Sandra
    Wong, A.
    Orlowski, R. Z.
    Jagannath, S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 7
  • [20] Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
    Vij, Ravi
    Wang, Michael
    Jagannath, Sundar
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    Kavalerchik, Edward
    Huang, Mei
    Siegel, David S.
    [J]. BLOOD, 2013, 122 (21)
12345